30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Globus Medical Posts 2Q16 Revenue -

Globus Medical (GMED) posted 2Q16 revenue of US $137MM, +3.1% vs. 2Q15. (U.S. $124.7MM, +2.7%, ex-U.S. $12.8MM, +5.7%) All growth is as reported.

ORTHOWORLD estimates 2Q16 segment revenue and as reported growth as follows.

  • Spine $131.3MM, +3.0%
  • Orthobiologics $6.2MM, +3.5%

GMED announced its intent to acquire the ex-U.S. operations and distribution channels of Alphatec Spine for $80MM in cash, plus a $30MM 5-year secured loan to ATEC. The transaction brings GMED access to the Japan market and doubles its international sales, citing a 3% share in the ex-U.S. market—a position that it states is unchanged after the acquisition.

For 2Q16, the company reported its Disruptive Technology segment growing at 10% on strong expandable technology, CREO MIS and biologics sales. Salesforce expansion challenges continued from 1Q into 2Q16, contributing to a -3% decline in Innovative Fusion sales. Leadership expects to regain salesforce growth momentum in 2H16.

The company remains on track to grow in-house manufacturing capacity to 50% by 2018. 

In light of the anticipated ATEC acquisition, GMED revised 2016 guidance to $575MM. ATEC ex-U.S. is expected to contribute $10MM to 2016 sales.

Sources: Globus Medical, Inc.; ORTHOWORLD Inc.



This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.